Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 33

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 33
---
 or incorporated by reference into this proxy statement/prospectus relating to Kadimastem. NLS and Kadimastem have both contributed to the information related to the Merger contained in this proxy statement/prospectus. You are cautioned not to rely on any information other than the information contained in or incorporated by reference into this proxy statement/prospectus. No one has been authorized to provide you with information that is different from that contained in or incorporated by reference into this proxy statement/prospectus. This proxy statement/prospectus is dated, 2025. You should not assume that the information contained in this proxy statement/prospectus is accurate as of any other date, nor should you assume that the information incorporated by reference into this proxy statement/prospectus is accurate as of any date other than the date of such incorporated document. The mailing of this proxy statement/prospectus to our shareholders will not create any implication to the contrary. This proxy statement/prospectus does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, or the solicitation of a proxy, in any jurisdiction in which or from any person to whom it is unlawful to make any such offer or solicitation in such jurisdiction. When used in this proxy statement/prospectus, all references to the “NLS,” refer to NLS Pharmaceutics Ltd.; all references to “Merger Sub” refer to NLS Pharmaceutics (Israel) Ltd., an Israeli company and a wholly owned subsidiary of NLS, formed for the purpose of effecting the Merger as described in this proxy statement/prospectus; all references to “Kadimastem” refer to and Kadimastem Ltd., an Israeli publicly traded company limited by shares (TASE: KDST); all references to “combined company” refer to the combined company immediately following completion of the Merger and the other transactions contemplated by the Merger Agreement; all references to “Common Share,” or “NLS Common Share” refer to a common share of NLS, 0.03 CHF nominal value per share, subject to changes pursuant to the NLS Meeting; all references to “Preferred Shares” or “NLS Preferred Shares” refer to the preferred shares of NLS, CHF 0.03 nominal value per share; all references to “Preferred Participation Certificates” or “NLS Preferred Participation Certificates” refer to the preferred participation certificates of NLS, CHF 0.03 nominal value per share; all